A
8.25
0.24 (3.00%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Atara Biotherapeutics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.5 |
| 技术平均移动指标 | -1.5 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | -5.0 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -1.96 |
|
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 22.44% |
| 机构持股比例 | 51.06% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Staley Capital Advisers Inc | 30 Jun 2026 | 50,000 |
该时间范围内无数据。
该时间范围内无数据。
投资组合